Objective: To evaluate the effects of multi-drug resistance gene (MDR1) gene factor which is significant in medicinereceptor relationship, on readmission to the emergency department (ED) and medical therapy modifications in patients with atrial fibrillation (AF) readmitting to the emergency department. Study Design: Descriptive, analytical study. Place and Duration of Study: Department of Emergency Medicine, Adnan Menderes University, Aydin, Turkey, from January 2016 to January 2017. Methodology: Fifty patients who did not have AF with rapid ventricular response, and 32 controls have been included in the study. Electronic recording system of the hospital was checked regularly to detect any readmission of these patients due to palpitation; and they were asked whether they had any ED readmission and any changes in medical therapy by calling them during the one-year period. Then, MDR1 1236TC, 2677TG and 3435TC gene analyses and medical treatment regimens of the patients after 1 year were compared. Results: No significant differences were found neither between the study and the control group nor between the genders in the study group regarding the results of MDR1 gene analyses. Besides, there were no differences in medical treatment regimens compared to MDR1 gene analyses in the group with AF. There were no statistically significant differences in the results of MDR1 gene analysis in patients whose medical treatment regimen had been changed during the one-year period. Conclusion: MDR1 gene analyses did not have any significant effect on the development of AF, readmission to the ED and modification of the treatment regimenin the Turkish population.
CITATION STYLE
Akoz, A., Turkdogan, K. A., Dagli, B., Kapci, M., Avcil, M., Bozkurt, G., & Duman, A. (2019). Does MDR1 analysis predict medical therapy modifications in patients with atrial fibrillation? Journal of the College of Physicians and Surgeons Pakistan, 29(7), 608–611. https://doi.org/10.29271/jcpsp.2019.07.608
Mendeley helps you to discover research relevant for your work.